![]() |
![]() |
![]() |
![]() |
PO-010 | Portohepatic hemodinamic disorders and increased blood ammonia at the steatohepatitis patients with initial liver fibrosis. | Tatiana Ermolova | ![]() |
![]() |
|||
PO-012 | Metabolic, biochemical, histopathological, and transcriptomic effects of resmetirom (MGL-3196) in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH | Michael Feigh | ![]() |
![]() |
|||
PO-027 | The NIF mouse - a unique way to distinguish between immunological and metabolic effects of NASH drug candidates | Sofia Mayans | ![]() |
![]() |
|||
PO-030 | Anti-oxidant, anti-inflammatory, and anti-fibrotic properties of triterpenic acids and phenylpropanoids on in vitro models of non-alcoholic steatohepatitis | Noel Salvoza | ![]() |
![]() |
|||
PO-035 | Is it a HIIT? High-Intensity Interval Training (HIIT) for the management of Non-alcoholic Steatohepatitis: patient experiences and perspectives | Shelley Keatng | ![]() |
![]() |
|||
PO-038 | The sustainable development goals as a driver of multisectoral action on NAFLD: the NAFLD-SDG framework | Jeffrey V Lazarus | ![]() |
![]() |
|||
PO-043 | Effects of bariatric surgery on quality of life in patients with non-alcoholic fatty liver disease | Jesús Funuyet-Salas | ![]() |
![]() |
|||
PO-047 | Impact of coping, vitality and metabolic pathology on depressive symptoms of patients with non-alcoholic fatty liver disease | Jesús Funuyet-Salas | ![]() |
![]() |
|||
PO-048 | Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy | Maria Pilar Ballester Ferré | ![]() |
![]() |
|||
PO-052 | Metabolic, biochemical, histopathological, and transcriptomic effects of dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH | Michael Feigh | ![]() |
![]() |
|||
PO-060 | Evaluating use of small molecule inhibitors of integrin function in NAFLD | Emma Shepherd | ![]() |
![]() |
|||
PO-070 | Design and evaluation of autophagy-inducing particles: towards a treatment of fatty liver disease? | Stavroula Zagkou | ![]() |
![]() |
|||
PO-073 | Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with nonalcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D) | Stephen Harrison | ![]() |
![]() |
|||
PO-075 | Crosstalk between ileal macrophage polarization and bacterial translocation in NASH: Role of PPAR alpha/delta dual activation | Andrew Hakeem | ![]() |
![]() |
|||
PO-078 | A Novel Quantitative Ultrasound Technique for Identifying Nonalcoholic Steatohepatitis | Feng Gao | ![]() |
![]() |
|||
PO-079 | Receptor Activity-Modifying Protein (RAMP2) alters glucagon trafficking in hepatocytes with functional effects on signalling | EmmaRose McGlone | ![]() |
![]() |
|||
PO-080 | Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven NAFLD: a pilot study | Zhongwei Chen | ![]() |
![]() |
|||
PO-082 | Sex influence the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven NAFLD | Gang Li | ![]() |
![]() |
|||
PO-083 | Biomaging, biochemical and genetic markers to stratify patients with metabolic associated fatty liver disease (MAFLD) in clinical practice: a single center cohort study | Laura De rosa | ![]() |
![]() |
|||
PO-087 | Rescuing the brain from non-alcoholic fatty liver disease: role of the monocarboxylate transporter-1 | Anna Hadjihambi | ![]() |
![]() |
|||
PO-088 | Silencing Cyclin M4 induces hepatic magnesium accumulation to resolve NASH | Jorge Simón | ![]() |
![]() |
|||
PO-091 | Diagnostic accuracy of liver steatosis measurements using artificial intelligence | Michael House | ![]() |
![]() |
|||
PO-092 | Metabolic association and liver fibrosis relationship in patients with non-alcoholic fatty liver disease and gallstone disease. | Tatyana Krolevets | ![]() |
![]() |
|||
PO-095 | GTX-011 improves portal hypertension, liver fibrosis and endothelial dysfunction in pre-clinical non-alcoholic steatohepatitis | Jordi Gracia-Sancho | ![]() |
![]() |
|||
PO-100 | Tocotrienol Rich Fraction Activates Farnesoid-X Receptor And Modulates Metabolites Profile of Non-Alcoholic Fatty Liver Disease In Mice Model | MohdDanial Mohd Efendy Goon | ![]() |
![]() |
|||
PO-101 | Characterization of disease progression and pharmacological intervention in the GAN diet-induced obese mouse model of NASH with advanced fibrosis and hepatocellular carcinoma | Michael Feigh | ![]() |
![]() |
|||
PO-102 | Subclinical liver damage detection by NMR spectroscopy | María Martín Grau | ![]() |
![]() |
|||
PO-107 | Hepatic steatosis contributes to the development of muscle atrophy via inter-organ crosstalk | Kenneth Pasmans | ![]() |
![]() |
|||
PO-110 | Hepatocyte cholesterol content modulates glucagon receptor signalling | EmmaRose McGlone | ![]() |
![]() |
|||
PO-111 | Transcriptomic signature of high fat diet murine models of NAFLD and its modulation by anti-steatotic treatments: a meta-analysis | Isabel Fuster-Martínez | ![]() |
![]() |
|||
PO-115 | Lower serum zinc levels are associated with severe hepatic necro-inflammation in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) | Sui-Dan Chen | ![]() |
![]() |
|||
PO-117 | Myeloid-specific fatty acid transport protein 4 deficiency in mice induces a shift towards M2 macrophages that leads to aggravation of NASH after high-fat/high-cholesterol feeding | Deniz Gcebe | ![]() |
![]() |
|||
PO-124 | Microbiome metabolites aggravate hepatic lipid deposition by decreasing mitochondrial function in an in vitro model of non-alcoholic fatty liver disease | Paula Boeira | ![]() |
![]() |
|||
PO-131 | Sterol lipids are associated with the plasticity of adipose tissue and promote a different response in women and men with severe obesity. | Gerard Baiges | ![]() |
![]() |
|||
PO-132 | A fast-induced model of fibrosing NASH: outcomes in different mice strains | Gabriel Bacil | ![]() |
![]() |
|||
PO-139 | The incremental Intrahepatic and extrahepatic cholangiocarcinoma risks in NAFL, NASH, and MAFLD patients: systematic review and meta-analysis | Boby Pratama Putra | ![]() |
![]() |
|||
PO-140 | New INSIGHTS into the role of MITOCHONDRIA in the development of NON-ALCOHOLIC FATTY LIVER DISEASE | Ins C.M. Simes | ![]() |
![]() |
|||
PO-144 | NAFLD vs MAFLD: South Asian NAFLD patients dont favour name change | Prajna Anirvan | ![]() |
![]() |
|||
PO-149 | One in ten cases of severe liver disease in the general population is attributable to type 2 diabetes | Ville Tapio Mnnist | ![]() |
![]() |
|||
PO-151 | Use of non-invasive tests to assess NAFLD patients in routine clinical practice | Emmanuel A Tsochatzis | ![]() |
![]() |
|||
PO-153 | Phosphatidylcholine attenuates the onset of a diet induced-NAFLD in mice | Victor Sánchez | ![]() |
![]() |
|||
PO-157 | AGILE3 development and validation: novel FibroScan based score to diagnose advanced fibrosis in non alcoholic fatty liver disease patients | Jerome Boursier | ![]() |
![]() |
|||
PO-160 | Prognostic value of AGILE scores in patients with non alcoholic fatty liver disease | Jerome Boursier | ![]() |
![]() |
|||
PO-162 | Cross-validation of non-invasive diagnostics for NAFLD in individuals with type 1 diabetes | jonathan mertens | ![]() |
![]() |
|||
PO-164 | Selective modulation of metabotropic glutamate receptor 5 protects obese-high fat diet mice from oxidative stress and lipid accumulation | Clarissa Berardo | ![]() |
![]() |
|||
PO-165 | Increased gut permeability may be associated with bacterial protease activity, not intestinal inflammation in patients with significant liver disease due to NAFLD | Roberta Forlano | ![]() |
![]() |
|||
PO-166 | The BAST score performs predicts the presence of liver disease better than FIB-4 and NAFLD fibrosis score in a cohort of patients with type-2 diabetes mellitus in primary care | Roberta Forlano | ![]() |
![]() |
|||
PO-167 | Liver senescence is linked to the development of NAFLD in young mice independently of obesity | IoannisI. Moustakas | ![]() |
![]() |
|||
PO-168 | Fibroblast Growth Factor 21 (FGF21) is a hepatokine involved in NAFLD progression. | Rocío Gallego-Durán | ![]() |
![]() |
|||
PO-169 | Quantification of EPCAM CD133 microvesicles: a MAFLD biomarker | Sheila Gato Zambrano | ![]() |
![]() |
|||
PO-170 | MiRNA-200b-3p overexpression is linked to NASH phenotype in both human and animal settings | Rocío Montero-Vallejo | ![]() |
![]() |
|||
PO-171 | Statin use is associated with significantly lower risk of high-risk NAFLD among patients with type 2 diabetes. A propensity-matched analysis from NHANES 2017-2018 | Eduardo Vilar Gomez | ![]() |
![]() |
|||
PO-172 | Relationship between serum and hepatic levels of Zn and Fe versus fatty acid composition in a rat model of NASH | LauraGiuseppina Di Pasqua | ![]() |
![]() |
|||
PO-174 | Waist and Hip Circumference are Independently Associated with Risk of Liver Disease in Population-Based Studies | Oscar Danielsson | ![]() |
![]() |
|||
PO-175 | The relationship between the frequency of drinking and incidence of fatty liver in Japanese cohort undergoing health checkups during the period 2008-2019 | Aya Sugiyama | ![]() |
![]() |
|||
PO-176 | The natural history of pediatric Non-alcoholic Fatty Liver Disease: a long term follow-up study. | Laura Draijer | ![]() |
![]() |
|||
PO-178 | Neddylation inhibition reduces liver steatosis in MAFLD mice models by promoting hepatic fatty acid oxidation via DEPTOR-mTOR axis | MARINA SERRANO MACIÁ | ![]() |
![]() |
|||
PO-182 | Association of PNPLA3 with the development of arterial stiffness in young patients with non-alcoholic fatty liver disease | Anastasiia Radchenko | ![]() |
![]() |
|||
PO-184 | Vitamin D Regulated MicroRNA Pathway and the Molecular Pathogenesis of Metabolic-associated Fatty Liver Disease | Zixuan Zhang | ![]() |
![]() |
|||
PO-186 | Short-term gluten-free diet is effective in reducing Controlled Attenuation Parameter and Body Mass Index in patients with Non-Alcoholic Steatohepatitis | Angelo Armandi | ![]() |
![]() |
|||
PO-187 | INT-747 ameliorates NASH pathogenesis by inhibiting hepatic diacylglycerol acyltransferase -2 mediated triglyceride synthesis in mice | Balasubramaniyan Vairappan | ![]() |
![]() |
|||
PO-190 | Single-cell analysis of NAFLD induced by high fat diet in rat | Fumihiko Takeuchi | ![]() |
![]() |
|||
PO-193 | Anti-inflammatory and anti-fibrotic effect of icosabutate as mono- or combination therapy with a GLP-1 receptor agonist, a FXR agonist or an ACC inhibitor in a dietary mouse model of progressive fibrosis | David Fraser | ![]() |
![]() |
|||
PO-197 | Menopausal women with NAFLD show impaired metabolism of branched chain amino-acids | Roberta Forlano | ![]() |
![]() |
|||
PO-203 | 4-methylpyrazole attenuates the development of diet-induced NAFLD | Katharina Burger | ![]() |
![]() |
|||
PO-205 | Mitochondria-targeted antioxidant based on caffeic acid AntiOxCIN4 prevented hepatic lipid accumulation by avoided Western Diet-induced autophagic blockage | Ricardo Fernando Santos Amorim | ![]() |
![]() |
|||
PO-206 | The activation of Liver X Receptor alpha in the gut protects the liver by the NASH-related damage | gessica lioci | ![]() |
![]() |
|||
PO-207 | Nonalcoholic steatohepatitis modifies liver and plasma phospholipids profile from patients with morbid obesity | Helena Castañé | ![]() |
![]() |
|||
PO-208 | A little is better than nothing: very low alcohol consumption is associated with lower prevalence of cirrhosis and HCC in patients with NAFLD | Bernardo Stefanini | ![]() |
![]() |
|||
PO-215 | A 3D in vitro throughput-based discovery approach for ing NASH drug candidates | Simon Strbel | ![]() |
![]() |
|||
PO-220 | Rising indication of non-alcoholic steatohepatitis as transplant indication in historically low risk areas | Laura Martínez Arenas | ![]() |
![]() |
|||
PO-221 | TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models | Miriam Longo | ![]() |
![]() |
|||
PO-222 | The I148M PNPLA3 variant mitigates Niacin beneficial effects: how the genetic screening in nonalcoholic fatty liver disease patients gains value | Erika Paolini | ![]() |
![]() |
|||
PO-223 | MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients | Marica Meroni | ![]() |
![]() |
|||
PO-225 | Outcomes of postmenopausal women with non-alcoholic fatty liver disease (NAFLD) | Chioma Izzi-Engbeaya | ![]() |
![]() |
|||
PO-229 | Preclinical animal models for nonalcoholic steatohepatitis (NASH) and their pharmacological validation | Gabe Berkowitz | ![]() |
![]() |
|||
PO-230 | Targeting the pro-inflammatory phenotype of adipose tissue macrophages using a dextran-nanocarrier ameliorates liver fibrosis and inflammation in a mouse model of NAFLD | Celia Martínez Sánchez | ![]() |
![]() |
|||
PO-231 | Cognitive dysfunction is associated with systemic inflammation and neuroinflammation in a rodent model of non-alcoholic steatohepatitis | Anne Catrine Daugaard Mikkelsen | ![]() |
![]() |
|||
PO-234 | Assessment of systemic inflammation by 3D MR Elastography in obese patients treated with bariatric surgery | Jiahui Li | ![]() |
![]() |
|||
PO-237 | Gender differences in characteristics of adolescents with non-obese nonalcoholic fatty liver disease | Oyekoya Ayonrinde | ![]() |
![]() |
|||
PO-239 | Ankle brachial index and all-cause and cardiovascular mortality in patients with NAFLD | Stefano Ciardullo | ![]() |
![]() |
|||
PO-240 | Intestinal microbiota in obese children with non-alcoholic fatty liver disease depending on the gallbladder function | Nataliya Zavhorodnia | ![]() |
![]() |
|||
PO-242 | Reduction in fibrosis and steatohepatitis imaging and biomarkers in 52-week resmetirom non-alcoholic steatohepatitis trial | Stephen Harrison | ![]() |
![]() |
|||
PO-244 | Intestinal microbiota features in obese children with non-alcoholic fatty liver disease depending on the grade of steatosis | Nataliya Zavhorodnia | ![]() |
![]() |
|||
PO-249 | Identification of new potential biomarkers to follow steatohepatitis in patients with Non-Alcoholic/Metabolic Associated Fatty Liver disease | Douglas Maya Miles | ![]() |
![]() |
|||
PO-250 | Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice | Mohammad Kabbani | ![]() |
![]() |
|||
PO-251 | increase metabolic dysfunction fatty liver disease related hepatocellular carcinoma in Egypt over a decade of period | Yasser Fouad | ![]() |
![]() |
|||
PO-253 | A cholestatic pattern predicts liver-related events in patients with nonalcoholic fatty liver disease | Grazia Pennisi | ![]() |
![]() |
|||
PO-258 | Hepatologists awareness and knoweledge towards NAFLD and familiarity with renaming from NAFLD to MAFLD | Yasser Fouad | ![]() |
![]() |
|||
PO-259 | Eating habits in patients affected by non-alcoholic steatohepatitis and type 2 diabetes mellitus | Lucia Brodosi | ![]() |
![]() |
|||
PO-260 | EUropean Patient cEntric clinicAl tRial pLatform (EU-PEARL): generating an integrated research platform to revolutionizing drug development in NASH | Juan M. Pericàs | ![]() |
![]() |
|||
PO-261 | Liver related and extrahepatic events occurrence in patients with non alcoholic fatty liver disease: a competing risk analysis | Grazia Pennisi | ![]() |
![]() |
|||
PO-269 | Hepatoprotective activity of Juglans regia stem bark ethanolic extract on CCl4 induced liver injury rat model | Bipindra Pandey | ![]() |
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|